Bladder Cancer — R115777 in Treating Patients With Advanced Bladder Cancer
Citation(s)
A Phase II Trial of R115777, an Oral Farnesyltransferase Inhibitor (FTI) in Previously Untreated Patients With Advanced Urothelial Tract Transitional Cell Carcinoma